# Outcomes associated with higher relational continuity in the treatment of persons with asthma or chronic obstructive pulmonary disease: A systematic review

Per Lytsy,<sup>a,b</sup>\* Sven Engström,<sup>c</sup> Mirjam Ekstedt,<sup>d</sup> Ingemar Engström,<sup>e</sup> Lars Hansson,<sup>f</sup> Lilas Ali,<sup>g</sup> Maja Kärrman Fredriksson,<sup>a</sup> Jan Liliemark,<sup>a</sup> and Jenny Berg<sup>a</sup>

<sup>a</sup>SBU – Swedish Agency for Health Technology Assessment and Assessment of Social Services

<sup>b</sup>Department of Clinical Neuroscience, Karolinska Institutet, Sweden

<sup>c</sup>Futurum, Region Jönköping County, Jönköping, Sweden

<sup>d</sup>Department of Health and Caring Sciences, Linnaeus University, Kalmar, Sweden

<sup>e</sup>University Health Care Center, Faculty of Medicine and Health, Örebro University, Sweden

<sup>f</sup>Department of Health Sciences, Lund University, Sweden

<sup>9</sup>Institute of Health and Care Sciences, University of Gothenburg, Sweden

# Summary

**Background** Asthma and chronic obstructive pulmonary disease (COPD) are chronic conditions where relational continuity of care, as in regularly meeting the same health care provider, creates opportunities for monitoring and adjustment of treatment based on an individual's changing needs, potentially affecting quality of delivered care. The aim of this systematic review was to investigate the effects of relational continuity in the treatment of persons with asthma or COPD.

**Methods** Eleven databases (CINAHL, Medline, PsycINFO, Scopus, Embase, Cochrane Library, Database of Systematic Review of Effects, DARE, Epistemonikos, NICE Evidence Search, KSR Evidence and AHRQ) were searched between January I, 2000, and February I - 4, 2021, for controlled and observational studies about relational continuity and health outcomes for persons with asthma and/or COPD. Inclusion criteria were studies investigating an index or aspect relevant to relational continuity between a health professional/team of health professionals and patients. After screening, and assessment of study relevance and quality by at least two independent reviewers, studies with acceptable risk of bias were included and summary data was extracted from the publications. Main outcomes were mortality, morbidity (including health care utilization) and cost measures. Syntheses without metanalyses were performed due to considerable study heterogeneity. The certainty of the summarized result was assessed using GRADE (the Grading of Recommendations Assessment, Development and Evaluation). PROSPERO study registration number: CRD42020196518.

**Findings** We identified 2824 unique references and included 15 studies (14 observational and 1 randomized controlled trial) in the review, from which results were derived for six outcomes. For persons with asthma or COPD we found that higher compared to lower relational continuity of care prevents premature mortality (low certainty; 2 studies, 111 545 participants), lowers risk of emergency department visits (low certainty, 5 studies, 362 305 participates) and risk of hospitalization (moderate certainty, 9 studies, 525 716 participants), and lowers health care costs (low certainty; 4 studies, 390 682 participants). Results regarding treatment adherence (1 study, 971 participants) and patient perceptions (3 studies, 2026 participants) were assessed as having very low certainty.

Interpretation Low to moderate certainty evidence suggests that higher versus lower relational continuity of care for persons with asthma or COPD prevents premature mortality, lowers risks of unplanned health care utilization and reduces health care costs. The results may be of value when planning care for individuals and for policymakers in organizing health care and developing guidelines for treatment and follow-up routines.

## Funding None.

**Copyright** © 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

**Keywords:** Relational continuity; Continuity of care; Asthma; Chronic obstructive pulmonary disease; Mortality; Health care utilization

#### eClinicalMedicine 2022;49: 101492 Published online xxx https://doi.org/10.1016/j. eclinm.2022.101492

<sup>\*</sup>Corresponding author at: Dr Per Lytsy, Swedish Agency for Health Technology Assessment and Assessment of Social Services, Stockholm, 113 43, Sweden. Telephone 46-8-4123258.

E-mail address: per.lytsy@sbu.se (P. Lytsy).

#### **Research in context**

#### Evidence before this study

Prior the study start we performed test literature searches in several databases, the latest in MEDLINE on March 25, 2020, using the search terms "chronic obstructive", "lung" or "pulmonary disease" or "asthma", and "continuity of patient care" or "continuity of care". The results indicated that there were published primary studies about the topic, but that existing systematic reviews had addressed management rather than relational continuity and, furthermore, focused on mortality only.

#### Added value of this study

To the authors' best knowledge this is the first systematic review addressing the effects of relational continuity of care in persons with asthma and/or COPD. Low to moderate certainty evidence suggests that higher versus lower relational continuity of care for persons with asthma or COPD prevents premature mortality, lowers risks of unplanned health care utilization and reduces health care costs. The results may be of value for health professionals when planning care for individuals, and for policymakers in organizing health care, estimating possible reductions in hospitalization and emergency department costs, and developing guidelines for treatment and follow-up routines.

#### Implications of all the available evidence

Since this is the first systematic review addressing the effects of relational continuity of care in these populations, it can form a basis for care planning, organization and guideline development in this field.

## Introduction

Asthma and chronic pulmonary disease (COPD) are among the leading causes of morbidity and mortality in the world<sup>1</sup>, contributing to high direct costs for health service utilization and drug use as well as indirect costs due to reduced productivity.<sup>2</sup> While these noncommunicable diseases are chronic and not curable, continuous monitoring and management may facilitate optimal control of symptoms, prevent deterioration and unnecessary health care utilization, ultimately having positive effects on patients' quality of life.

Research around continuity of care tends to distinguish between three types of continuity: *informational continuity* —the use of information of past events and personal circumstances to inform current care; *management continuity* —the consistent and coherent approach within the health care system to manage a health condition that is responsive to a patient's changing needs, and *relational continuity* which focuses on the ongoing relationship between a patient and one or more health care providers.<sup>3,4</sup> A review of the different ways to measure longitudinal and relational continuity of care revealed a diversity of indices which could be classified into having a primary focus on either duration, density of visits, dispersion of providers, sequence of providers or subjective measurements.<sup>5</sup> Relational continuity, as in meeting the same physician or other care provider over time, may facilitate mutual understanding of the condition and the individual's changing needs, which could improve quality of care as well as reduce the need of emergency care. Thus, it was hypothesized that relational continuity would be positively associated with favorable health outcomes and reduced need of unplanned health care utilization.

The aim of this systematic review was to investigate treatment outcomes, including effects on resource use and costs, associated with receiving higher relational continuity of care for patients with asthma or COPD.

#### Methods

This systematic review was conducted at the Swedish Agency for Health Technology Assessment and Assessment of Social Services, SBU, adhering to the PRISMA reporting guidelines and following a protocol pre-registered on PROSPERO (CRD42020196518). Results of the other study population mentioned in the protocol will be reported separately. Due to considerable heterogeneity in included studies it was not possible to conduct meta-analyses. Thus, syntheses without meta-analysis were used to summarize outcomes associated with receiving higher relational continuity of care for patients with asthma or COPD. The certainty of the evidence was assessed using the GRADE-framework.<sup>6</sup>

#### Research question and selection criteria

The research question and the inclusion criteria were formulated using the PICO/PECO structure. The population had to have a diagnosis of asthma or COPD and be at least 18 years of age. If the study population was mixed, results were included if they were specified for relevant age groups as well as for asthma and/or COPD populations, or if most participants had a relevant condition.

The exposure had to be relevant to relational continuity of care in that it used a continuity index or measure of duration, density, dispersion, sequencing, fragmentation, or discontinuation of regular care to either a specified person or a team of health care professionals. The exposure should have been present for at least 12 months. Intervention studies were required to alter a dimension of continuity of care, but were not allowed to involve other components, such as enhanced care, education, support groups, etc. Consensus in the project group was used to determine if the intervention fulfilled these criteria and the follow-up time was sufficiently long to address the research question.

The main outcomes were mortality, morbidity (symptoms and functioning) and health care utilization (emergency department visits, hospitalizations). Additional outcomes were adherence to prescribed medical treatment, relevant laboratory measures and subjective measures such as patient satisfaction and quality of life.

Controlled studies and observational studies (cohort and register studies) were included. Studies that identified themselves as cross-sectional were included if the continuity exposure preceded the measurement or occurrence of the outcome, for example in retrospective register data.

#### Literature search

A search strategy was developed, tested and further developed by an information specialist with the assistance of researchers in the project group. Blocks of search terms about the populations and the exposure 'continuity of patient care' were used in subject headings and in titles and abstracts. Literature searches were performed between January 1, 2000, and February 1-4, 2021, by the information specialist in the following databases: CINAHL, Medline, PsycINFO, Scopus, Embase, Cochrane Library, Database of Systematic Review of Effects, DARE, Epistemonikos, NICE Evidence Search, KSR Evidence and AHRQ. The search was performed in May to June 2020 and was updated in early February 2021. The searches were complemented with literature identified from reference lists of published literature. Grey literature, books and conference abstracts were not considered. The full search strategy is provided in Supplement 1.

## Screening and assessment of relevance

Screening of titles and abstracts to determine if they fulfilled the inclusion criteria was performed independently by two researchers (PL, JB) using the Covidence platform (covidence.org). Disagreements were resolved through discussion in the larger research group and, if questions remained, studies were included to be read in full length. Two researchers with expert knowledge in the field (SE, ME) then independently read all included articles in full length to determine their relevance in terms of the set inclusion criteria. Disagreements were discussed in the larger research group. If there was any ambiguity about the relevance of the exposure, for example whether the measure of continuity was relating to a person or a clinic, the project group decided to include the article in order not to lose too much information and the implications of the indirectness were handled when rating the quality of the evidence.

## Quality assessment

The quality of randomized controlled trials was assessed using the RoB2 instrument (version 2 of the Cochrane risk-of-bias tool for randomized trials). For observational studies an instrument was developed based on a preliminary tool for assessing risk of bias of exposure studies, ROBINS-E, and other risk of bias assessment tools used at the Swedish Agency for Health Technology Assessment and Assessment of Social Services. The instrument covered different domains that may affect risk of bias: confounding, exposure, attrition, measurement and analysis of outcomes, reporting, and conflict of interests. It has a similar approach as the ROBINS-I tool, developed for assessing risk of bias in non-randomized studies of interventions.7 It specifically addresses concerns of bias due to confounding and selection, and aims at assessing risk of bias compared to a prefect hypothetical target trial, thus providing assessments on a scale comparable to those addressed in randomized trials. Overall risk of bias was classified as low, moderate, high or unacceptable. Articles considered to have unacceptable risk of bias for a given outcome were excluded from further analysis. A translated version of the instrument used to assess risk of bias in observational studies is available in Supplement 2.

# Data analysis, synthesis and rating of the certainty of evidence

Data was extracted by one researcher and checked for correctness by three others. Data extracted included study type, country where the study was performed, type of study population, participants' age and sex, measurement of exposure, type of analysis, handling of confounders and main results/summary statistics for the outcomes.

Due to substantial heterogeneity in the way the exposure had been measured, categorized and analyzed it was not possible to perform meta-analyses. Instead, results from studies about the main and additional outcomes were synthesized without meta-analysis, where the overall result for each category of outcome was formulated as a summarizing result regarding effect. The GRADE framework was used to rate the certainty of evidence for each statement as high, moderate, low or very low.<sup>8</sup> Five domains were considered: risk of bias, inconsistency of results, indirectness, imprecision and publication bias. Studies with high risk of bias were included so as not to lose information in an area with potentially few studies per outcome. Instead, study quality and any indirectness of the continuity measure were taken into consideration when rating the certainty of the evidence. As we included studies with both randomized and nonrandomized design and used a risk of bias tool for nonrandomized studies, which addresses consequences of selection and confounding as an integrated part of the tool, the initial GRADE certainty rating started at high certainty, as suggested by the GRADE working group.<sup>9</sup> Generally, studies using observational data for causal analysis were considered having at least moderate risk of bias, due to a potential risk of residual confounding.

The project group strived to derive precise statements with lower certainty rather than the other way around, as more precise statements were considered to be of higher value for health care professionals and decision makers.

#### Role of the funding source

There was no funding source for this study. All authors had access to the included studies and the extracted data. All approved on the decision to submit and gave one person (PL) final responsibility to do so.

### Results

We identified 2824 unique references, of which 36 articles were read in full text. Sixteen articles fulfilled the inclusion criteria,<sup>10-25</sup> of which one<sup>25</sup> was later excluded because of an unacceptable risk of bias. Of the 15 included articles, 14 were based on observational data, mainly retrospective cohort studies, and one<sup>24</sup> was a randomized controlled study. Two articles<sup>17,18</sup> presented analyses on almost the same study population but for different outcomes. Of the 15 included articles none were deemed to have low risk of bias, twelve had moderate and three high risk of bias. The identification, selection and outcome of risk of bias assessments of included studies is shown in Figure 1 (PRISMA flow chart of searched and included studies) and the risk of bias assessments and reasons for exclusion of nonincluded studies are shown in Supplement 3 and 4, respectively. A summary of characteristics of the included studies is shown in Table 1.

The studies were mainly performed in Asia (Korea or Taiwan), Europe or the United States and reported results from analyses based on more than 500 000 participants with either asthma or COPD. There was considerable heterogeneity among studies in the way continuity had been measured and operationalized in the analyses, as well as in the choice of statistical modelling. The reported outcomes allowed categorization into the following summarized outcomes: mortality (two studies), emergency department (ED) visits (five studies), hospitalizations (nine studies), costs (four studies), adherence to treatment (one study) and a composite measurement of health care experience, knowledge of self-management and health-related quality of life (three studies). No results were found reporting outcomes on laboratory measures.

Below are the results for the different outcomes and a brief description of the studies included in each outcome category. Table 2 provides a summary of the results and evidence gradings. Supplement 5 provides effects in asthma and COPD subgroups, respectively, and more information about the reasons for reductions in the certainty of the evidence. Supplement 6 provides detailed informational about the included studies.

## Mortality

Two studies investigated the association between relational continuity of care and mortality in altogether III 425 persons with either asthma or COPD. Cho et al reported a median survival for those with a low COC index score of 2.92 years compared to 4.00 years for those with a high COC-index score (p<0.0001). The adjusted hazard ratio for low versus high COC was I.22 (95% CI I.09 to I.36).<sup>10</sup> The study by Einarsdottir et al compared different quintiles of a regularity-index score, where all four analyses showed a consistent trend of reduced hazard ratios for those with higher compared to lower regularity; however, only one analysis gave statistically significant results.<sup>12</sup>

The overall result for the outcome mortality was: "Higher relational continuity of care for persons with asthma or COPD prevents premature mortality". The certainty of the evidence was considered to be low for the population asthma/COPD and COPD separately, and very low for asthma alone.

#### Hospitalization

Nine studies with a total of 525 716 participants investigated the effect of relational continuity of care on risk of future hospitalization.<sup>12-16,18,19,21,22</sup> The definition of hospitalization varied somewhat, but typically concerned hospitalization, re-hospitalization or conditionspecific hospitalization. The analytic approaches also varied, where some studies compared lower to higher continuity while others did the opposite. All results were, however, consistent in showing favorable outcomes for those with higher continuity of care, with the exception of one study with a non-statistically finding in one subpopulation.<sup>22</sup>

The overall result on the outcome hospitalization was: "Higher relational continuity of care for persons with asthma or COPD lowers risk of hospitalization by a moderate to high degree". The certainty of the evidence was considered to be moderate for the population asthma/COPD and COPD separately, and low for the asthma population.

### Emergency department visits

Five studies with a total of 362 305 participants investigated the effect of relational continuity of care on the risk of future ED-visits.<sup>14-17,21</sup> Two studies had overlapping populations.<sup>16,17</sup> All studies used various categorizations of the COC index in multiple logistic regressions or proportional hazard models.




Figure 1. PRISMA flow chart of searched and included studies.

Health care costs

All results suggested an association between having higher continuity of care and lower risk of future EDvisits. The overall result on the outcome ED-visits was formulated as: "*Higher relational continuity of care for persons with asthma or COPD lowers risk of ED-visits by a moderate to high degree*". The certainty of the evidence was assessed as low for the population asthma/COPD, as well as for asthma and COPD separately.

Four studies covering a total of 390 685 individuals investigated the effect of relational continuity of care on health care costs.<sup>13-15,21</sup> There were uncertainties about what costs were included, how they were calculated and how the results were presented, for example as relative or absolute differences and for different categorizations of continuity. However, all four studies were consistent

Author Year	Study type Country/region Data period	Population N Age	Measure of exposure (continuity)	Outcome(s) Type(s) of analysis	Reported results	Overall risk of bias	Comment
Cho et al. 2015	Retrospective cohort South Korea Data period: 2002- 2012	COPD n=3090 Mean age 69.0 years	CoC index, dichoto- mized in analysis	All-cause mortality Cox regression	Low versus high COC: HR 1.22 (95% CI 1.09 to 1.36).	Moderate	Continuity measure based on medical institution rather than individual physi- cian. COC included as time- dependent covariate in analysis.
Corsico et al. 2007	Cross sectional survey Mainly European countries Data periods 1990—1994 and 1998—2002, mean length of follow up 8.1 years	Asthma n=971 Mean age at first survey 34.0 years	Regular appoint- ments with doc- tor or nurse	Adherence to pre- scribed anti-asth- matic treatment Logistic regression	<ul> <li>Having regular appointments and <i>increased</i> adherence: OR 3.32 (95% Cl 1.08 to 10.17).</li> <li>Having regular appointments and <i>persistent</i> adherence: OR 1.23 (95% Cl 0.55 to 2.75).</li> </ul>	High	Self-reported data for exposure and out- come variables.
Einarsdottir et al. 2010	Retrospective cohort Australia Data period 1992—2006	Chronic respiratory disease (asthma, COPD, Emphy- sema, chronic bronchitis) n=108 455 Mean age 72.7 years	General practi- tioner regularity score (0-1), com- parison of quin- tiles in analyses	All-cause mortality. First CRD hospitaliza- tion Cox regression	<ul> <li>All-cause mortality for least regular continuity quintile compared to:</li> <li>2<sup>nd</sup> least regular: HR 0.90 (95% Cl 0.79 to 1.01)</li> <li>Medium regular: HR 0.84 (95% Cl 0.75 to 0.95)</li> <li>2<sup>nd</sup> most regular: HR 0.90 (95% Cl 0.80 to 1.01)</li> <li>Most regular: HR 0.95 (95% Cl 0.83 to 1.08)</li> <li>First CRD hospitalization for least regular continuity quintile compared to:</li> <li>2<sup>nd</sup> least regular: HR 0.92 (95% Cl 0.83 to 1.00)</li> <li>Medium regular: HR 0.84 (95% Cl 0.77 to 0.92)</li> <li>2<sup>nd</sup> most regular: HR 0.74 (95% 0.67 to 0.86)</li> </ul>	Moderate	

www.thelancet.com Vol 49 Month July, 2022

6

Author Year	Study type Country/region Data period	Population N Age	Measure of exposure (continuity)	Outcome(s) Type(s) of analysis	Reported results	Overall risk of bias	Comment
Frandsen et al.	Retrospective	COPD	Care fragmentation	Hospitalisations of	Regression coefficients for 1 SD change in fragmenta-	High	Possible overlap
2015	cohort study	n=32 916	index	ambulatory care-sen-	tion in COPD subgroup:		between compo-
	US	Mean age 46.3		sitive conditions	Any ACSC hospitalizations: 25% least fragmented vs.		nents of exposure
	Data period	years		Medicare costs	29% most fragmented.		measure and resour-
	2004—2008			Linear regression	Costs: USD 12 702 least fragmented vs. USD 19 368		ces included in cost
					most fragmented.		calculations.
Hong et al.	Retrospective	Asthma	Continuity of Care	Hospitalization	Asthma, hospitalization:	Moderate	Continuity measure
2010	cohort study	n=129 550	index, compari-	Emergency department	low vs. high COC, OR: 2.07 (95% Cl 1.92 to 2.23)		based on medical
	South Korea	Mean age 72.0	son of terciles in	visits/	medium vs. high COC, OR 1.56 (95% Cl 1.45 to 1.68)		institution rather
	Data period	years	analyses	Logistic regression	Asthma, ED visits:		than individual physi-
	2002—2006	COPD		Healthcare costs/ Linear	low vs. high COC, OR: 2.25 (95 % Cl 1.87 to 2.70)		cian.
		n=131 512		regression	medium vs. high COC, OR: 1.38 (95 % Cl 1.14 to 1.67).		Possible overlap
		Mean age 72.1			Asthma, healthcare costs:		between compo-
		years			low vs. high COC, regression coefficient: 0.025		nents of exposure
					(p<0.001)		measure and resour- ces included in cost
					medium vs. high COC, regression coefficient: 0.022		calculations.
					(p=0.001). COPD, hospitalization:		calculations.
					low vs. high COC, OR: 1.99 (95% Cl 1.86 to 2.13)		
					medium vs. high COC, OR: 1.50 (95% Cl 1.41 to 1.61).		
					COPD, ED visits:		
					low vs. high COC, OR: 1.77 (95% Cl 1.45—2.17)		
					medium vs. high COC, OR: 1.30 (95% Cl 1.06 to 1.59).		
					COPD, costs:		
					low vs. high COC, regression coefficient: 0.123		
					(p<0.001)		
					medium vs. high COC, regression coefficient: 0.077		
					(p<0.001).		

Table 1 (Continued)

v

Author Year	Study type Country/region Data period	Population N Age	Measure of exposure (continuity)	Outcome(s) Type(s) of analysis	Reported results	Overall risk of bias	Comment
Hussey et al.	Retrospective	COPD	Continuity of Care	Hospitalizations	Hospitalization per 0.1 unit increase in COC index:	Moderate	Cross-sectional analysis
2014	cohort study	n=76 520	index, assessed	Emergency department	OR 0.95 (95% Cl 0.94—0.96).		with unclear mea-
	US	Age ≥65 years	as deciles in	visits	ED visits per 0.1 unit increase in COC index:		surement period for
	Data period		analyses	Logistic regression	OR 0.93 (95% Cl 0.92—0.93).		exposure. Possible
	2008-2009			Costs of care per epi-	Total episode costs per 0.1 increase in COC index: 6.3%		overlap between
				sode	lower costs.		components of expo-
				Linear regression			sure measure and
							resources included in
							cost calculations.
Kao et al. 2016	Retrospective	Kao 2016: Asthma	Continuity of Care	Kao 2016: Avoidable	Avoidable hospitalizations, low vs. high COC:	Moderate	Two articles based on
and 2017	cohort study	n= 3356	index.	hospitalizations.	HR 2.68 (95% CI 1.55 to 4.63)		same study reporting
	Taiwan	Age ≥65 years	Kao 2016: divided	Kao 2017: Emergency	moderate vs. high COC:		two different out-
	Data period	Kao 2017:	into low (<0.5),	department visits.	HR 1.49 (95% CI 0.80 to 2.75)		comes, however,
	2004—2013	Asthma	medium	Cox regression	ED visits, low vs. high COC:		without any refer-
		3356	(0.5—0.99) and		HR 2.11 (95% CI 1.37 to 3.25)		ence to the other.
		Age ≥65 years	high (1).		moderate vs. high COC:		
			Kao 2017: divided		HR 1.15 (95% CI 0.70 to 1.87).		
			into low (<0.47),				
			medium				
			(0.48—0.99) and				
			high (1).				
Kao et al. 2019	Retrospective	Asthma-COPD	Continuity of Care	ED visits.	ED visits, low vs. high COC:	Moderate	Based on same data-
	cohort study	overlap	index. Divided	Hospitalizations for	HR 2.80 (95% CI 1.45 to 5.38), moderate vs. high, COC:		base extraction as
	Taiwan	n=1141	into low	COPD or asthma.	HR 2.69 (95% Cl 1.47 to 4.93).		Kao 2016 and Kao
	Data period	Mean age 74.4	(0—0.29),	Cox regression	Hospitalizations, low vs. high COC:		2017.
	2004—2013	years	medium		HR 1.80 (95% CI 1.03 to 3.13),		
			(0.3—0.99), high		moderate vs. high COC:		
			(1).		HR 1.72 (95% CI 1.04 to 2.83).		

Table 1 (Continued)

œ

Author Year	Study type Country/region Data period	Population N Age	Measure of exposure (continuity)	Outcome(s) Type(s) of analysis	Reported results	Overall risk of bias	Comment
Lin et al. 2017	Retrospective	COPD	Continuity of Care	COPD-related hospital-	Short-term COC:	Moderate	Article by Lin et al. pub-
	cohort study	n=2199	index over 2	isation.	low vs. high COC:		lished in 2015 used
	Taiwan	Age ≥40 years	time periods:	Logistic regression.	OR 1.59 (95% CI 0.91 to 2.76)		same cohort, but
	Data period		short term (1		medium vs. high COC:		included patients
	2005-2009		year and long		OR 1.89 (95% CI 1.07 to 3.33),		who died during first
			term (2 years)		Long-term COC:		two years of observa-
			divided into ter-		low vs. high COC:		tion period (total
			ciles in analyses.		OR: 1.98 (95% CI 1.00 to 3.94)		n=3015); analysis was
					medium vs. high COC:		only for long-term
					OR: 2.03 (95% Cl 1.05 to 3.94).		COC.
Love et al.	Cross sectional sur-	Asthma	Patient perception	Patient assessment of	Continuity of care significant (p=0.01) in predicting	High	Self-reported data. Out-
2000	vey with 12	n=404	of continuity,	care as provider com-	perception of provider communication, coefficient		comes do not directly
	months recall	Mean age 49.3	assessed on 4-	munication and	0.147.		measure patient
	US	years	item scale	patient influence	Continuity of care significant (p=0.02) in predicting		satisfaction.
	Data period 1997			Linear regression.	perception of patient influence, coefficient 0.144.		

Table 1 (Continued)

9

Author Year	Study type Country/region Data period	Population N Age	Measure of exposure (continuity)	Outcome(s) Type(s) of analysis	Reported results	Overall risk of bias	Comment
Svereus et al.	Retrospective	COPD	CoC index,	Hospitalisation	Lowest compared to highest COC quintile:	Moderate	Definition of continuity
2017	cohort study	n=20187	comparison of	Emergency department	Any hospitalization:		on clinic-level.
	Sweden	Age $\geq$ 55 years	quintiles in	visits	OR 2.17 (95% CI 1.95—2.43).		Concurrent measure-
	Data period		analyses	Logistic regression	Any emergency department visit:		ment of exposure
	2012-2013			Cost for healthcare and	OR 2.06 (95% CI 1.86-2.28).		and outcomes does
				pharmaceuticals	Relative increase in costs: 58 % (52-64 %).		not allow conclusions
				Linear regression	Second lowest compared to highest COC quintile:		about causality.
					Any hospitalization:		Possible overlap
					OR 1.68 (95% CI 1.50—1.87).		between compo-
					Any emergency department visit:		nents of exposure
					OR 1.66 (95% CI 1.50—1.84).		measure and resour-
					Relative increase in costs: 41 % (35-46 %).		ces included in cost
					Third lowest compared to highest COC quintile:		calculations.
					Any hospitalization:		
					OR 1.57 (95% CI 1.41-1.75).		
					Any emergency department visit:		
					OR 1.68 (95% CI 1.52—1.86).		
					Relative increase in costs: 32 % (27—37 %).		
					Fourth lowest compared to highest COC quintile:		
					Any hospitalization:		
					OR 1.40 (95% CI 1.28—1.56).		
					Any emergency department visit:		
					OR 1.41 (95% 1.28—1.56).		
					Relative increase in costs: 21 % (17–26 %).		

Author Year	Study type Country/region Data period	Population N Age	Measure of exposure (continuity)	Outcome(s) Type(s) of analysis	Reported results	Overall risk of bias	Comment
Swanson et al.	Retrospective	COPD	Three different	Readmission within	Germany:	Moderate	
2018	cohort study	Germany: n=6373	continuity of	30 days and 1 year.	OR for 30-day readmission:		
	Germany, Norway	Mean age: 73.3	care indices:	Logistic regression.	COCI 0.990 (95% CI 0.960—1.021)		
	Data period 2009	years	CoC index, UPC	Negative binominal	UPC 0.993 (95 % CI 0.955—1.032)		
	-14	Norway:	index and	regression.	SECON 0.987 (95 % CI 0.956—1.018)		
		n=13507	SECON index, all		Incidence rate ratio for 1-year readmission:		
		Mean age: 71.8	used as deciles		COCI 1.002 (95% CI 0.987—1.017)		
		years	in analyses		UPC 1.003 (95 % CI 0.985—1.021)		
					SECON 1.003 (95 % CI 0.989—1.018)		
					Norway:		
					OR for 30-day readmission:		
					COCI 0.987 (95% CI 0.967—1.008)		
					UPC 0.986 (95 % CI 0.962—1.010)		
					SECON 0.987 (95% CI 0.970-0.990)		
					Incidence rate ratio for 1-year readmission:		
					COCI 0.967 (95% CI 0.956—0.978)		
					UPC 0.961 (95% CI 0.948-0.974)		
					SECON 0.962 (95% CI 0.952—0.973)		
Wireklint et al. 2020	Cross-sectional cohort study	Asthma n=1442	Physician continu- ity (assignment	Patient-reported knowl- edge of self-manage-	OR of having sufficient knowledge of management of asthma exacerbations.	Moderate	Self-reported data.
	Sweden	Largest age group	to a patient-spe-	ment of worsening	Physician continuity vs. not:		
	2012 and 2015	40—59 years (41	cific physician)	asthma (defined as	OR 2.19 (95 % CI 1.62—2.96).		
		%)		exacerbations or			
				deteriorations)			
				Logistic regression			

Uljen et al.       Randomized con-       COPD       3 modes of care       Health Related Quality       No clinically relevant difference in CRO score (>0.5)       Moderate       Self-reported         2012       trolled trial       n=180       administration in       of Life measured with       was seen for different UPC scores.       exposure a         2012       The Netherlands       Mean age 64.5       primary care, of       self-administered       Pearson's correlation coefficient of difference in CRQ       outcome.         Data period       years       Chronic Respiratory       and personal continuity: 0.117.       exposure a       outcome.         2004-2006       mean age 64.5       miny of care and       Destronaic.       Pearson's correlation coefficient of difference in CRQ       outcome.         2004-2006       regular monitor-       Questionnaic.       Pearson's correlation coefficient of difference in CRQ       outcome.         2004-2006       ing as adjunct to       Pearson's correlation coefficient of continuity: 0.041.       and personal continuity: 0.041.       outcome.         2004-2006       ing as adjunct to       Pearson's correlation coefficient of continuity: 0.041.       and personal continuity: 0.041.       outcome.         2014       eaguer and continuity: 0.041.       usual care       nuity of care and change in CRQ       and mean of 18- and <t< th=""><th>Image: Health Related Quality       No clinically relevant difference in CRO score (&gt;0.5)       Moderate         ion in       of Life measured with       was seen for different UPC scores.       Moderate         e, of       self-administered       Pearson's correlation coefficient of difference in CRO       Vas         and personal continuity: 0.117.       Pearson's correlation       Pearson's correlation coefficient of difference in CRO         vito       Pearson's correlation       Pearson's correlation coefficient of difference in CRO       Pearson's correlation         vito       Pearson's correlation       and team continuity: -0.041.       Pearson's correlation         vito of care and       change in CRO       and team continuity: -0.041.       Pearson's correlation         vito of care and       change in CRO       between baseline       Pearson's correlation       Pearson's correlation         vito of care and       change in CRO       between baseline       Pearson's correlation       Pearson's correlation         vito of care and       change in CRO       Pearson's correlation       Pearson's correlation       Pearson's correlation         vito of care and       change in CRO       Pearson's correlation       Pearson's correlation       Pearson's correlation         vito of care and       change in CRO       Pearson's correlation       Pearson's correlat</th><th>Image: Health Related Quality       No clinically relevant difference in CRO score (&gt;0.5)       Moderate         ion in       of Life measured with       was seen for different UPC scores.       Moderate         e, of       self-administered       Pearson's correlation coefficient of difference in CRO       Moderate         vas       Chronic Respiratory       and personal continuity: 0.117.       Moderate         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Moderate         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Moderate         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Moderate         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Moderate         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Pearson's correlation         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Pearson's correlation         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Pearson's correlation         vitro       Pearson's correlation       Pearson's correlation coefficient of difference in CRO       Pearson's correlation         vitro       Pea</th><th></th><th>Data period</th><th>N Age</th><th>(continuity)</th><th></th><th></th><th>of blas</th><th></th></t<>	Image: Health Related Quality       No clinically relevant difference in CRO score (>0.5)       Moderate         ion in       of Life measured with       was seen for different UPC scores.       Moderate         e, of       self-administered       Pearson's correlation coefficient of difference in CRO       Vas         and personal continuity: 0.117.       Pearson's correlation       Pearson's correlation coefficient of difference in CRO         vito       Pearson's correlation       Pearson's correlation coefficient of difference in CRO       Pearson's correlation         vito       Pearson's correlation       and team continuity: -0.041.       Pearson's correlation         vito of care and       change in CRO       and team continuity: -0.041.       Pearson's correlation         vito of care and       change in CRO       between baseline       Pearson's correlation       Pearson's correlation         vito of care and       change in CRO       between baseline       Pearson's correlation       Pearson's correlation         vito of care and       change in CRO       Pearson's correlation       Pearson's correlation       Pearson's correlation         vito of care and       change in CRO       Pearson's correlation       Pearson's correlation       Pearson's correlation         vito of care and       change in CRO       Pearson's correlation       Pearson's correlat	Image: Health Related Quality       No clinically relevant difference in CRO score (>0.5)       Moderate         ion in       of Life measured with       was seen for different UPC scores.       Moderate         e, of       self-administered       Pearson's correlation coefficient of difference in CRO       Moderate         vas       Chronic Respiratory       and personal continuity: 0.117.       Moderate         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Moderate         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Moderate         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Moderate         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Moderate         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Pearson's correlation         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Pearson's correlation         vitro       Questionnaire.       Pearson's correlation coefficient of difference in CRO       Pearson's correlation         vitro       Pearson's correlation       Pearson's correlation coefficient of difference in CRO       Pearson's correlation         vitro       Pea		Data period	N Age	(continuity)			of blas	
trolled trialn=180administration in of Life measured withwas seen for different UPC scores.The NetherlandsMean age 64.5primary care, of self-administeredself-administeredPearson's correlation coefficient of difference in CRQData periodyearswhich one wasChronic Respiratoryand personal continuity. 0.117.2004-2006regular monitor-Questionnaire.Pearson's correlation coefficient of difference in CRQ1004-2006ing as adjunct toPearson's correlation coefficient of difference in CRQ101nusual carecoefficient of conti-101usual carecoefficient of conti-111usual carecoefficient of conti-112nuity of care andand team continuity: -0.041.113ethone baselineand mean continuity: -0.041.114and mean of 18- andand mean continuity: -0.041.115and mean of 18- andand mean continuity: -0.041.114and mean of 18- andand mean continuity: -0.041.115and mean of 18- andand mean continuity: -0.041.115and mean of 18- and24-month114measurements.and mean continuity: -0.041.115and mean of 18- andand mean continuity: -0.041.115and mean of 18- andand mean continuity: -0.041.115and mean continuity: -0.041.and mean continuity: -0.041.115and mean continuityand mean continuity: -0.041.116and mean continuityand mean continuity117and	Ion in       of Life measured with was seen for different UPC scores.         e. of       self-administered       Pearson's correlation coefficient of difference in CRQ         vas       Chronic Respiratory       and personal continuity: 0.117.         vas       Chronic Respiratory       and personal continuity: 0.117.         vitor-       Questionnaire.       Pearson's correlation coefficient of difference in CRQ         ritor-       Questionnaire.       Pearson's correlation coefficient of difference in CRQ         ritor-       Questionnaire.       and team continuity: -0.041.         nuity of care and       change in CRQ         dchange in CRQ       between baseline         and mean of 18- and       24-month         measurements.       measurements.	trolled trialn=180administration in of Life measured withwas seen for different UPC scores.The NetherlandsMean age 64.5primary care, of self-administeredself-administeredParson's correlation coefficient of difference in CRQData periodyearsWhich one wasChronic Respiratoryand personal continuity: 0.117.Data periodyearsChronic Respiratoryand personal continuity: 0.117.2004-2005regular montorQuestionnaile.Parson's correlation coefficient of difference in CRQ1004-2005regular montorQuestionnaile.Parson's correlation coefficient of difference in CRQ2004-2005regular montorOutoinParson's correlation1004regular montorQuestionnaile.Parson's correlation coefficient of difference in CRQ2004-2005regular montorParson's correlationParson's correlation coefficient of difference in CRQ2004-2005regular montorParson's correlationParson's correlation2004-2005regular montorParson's correlationParson's correlation2004-2005regular montorParson's correlationParson's correlation2004-2005regular montorParson's correlationParson's correlation </td <td></td> <td>iized con-</td> <td>СОРD</td> <td>3 modes of care</td> <td>Health Related Quality</td> <td>No clinically relevant difference in CRQ score (&gt;0.5)</td> <td>Moderate</td> <td>Self-reported data of</td>		iized con-	СОРD	3 modes of care	Health Related Quality	No clinically relevant difference in CRQ score (>0.5)	Moderate	Self-reported data of
ands     Mean age 64.5     primary care, of years     self-administered which one was     correlation coefficient of difference in CRQ       years     which one was     Chronic Respiratory     and personal continuity: 0.117.       regular monitor-     Questionnaire.     Pearson's correlation coefficient of difference in CRQ       ing as adjunct to     Pearson's correlation     and team continuity: 0.041.       usual care     coefficient of conti- nuity of care and change in CRQ     and team continuity: -0.041.       between baseline     nuity of care and change in CRQ     between baseline       and mean of 18- and 24-month     24-month     caresult	e, of self-administered Pearson's correlation coefficient of difference in CRQ vas Chronic Respiratory and personal continuity: 0.117. vitor- Questionnaire. Pearson's correlation coefficient of difference in CRQ into Pearson's correlation and team continuity: -0.041. coefficient of conti- nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.	e, of self-administered Pearson's correlation coefficient of difference in CRQ vas Chronic Respiratory and personal continuity: 0.117. Itron- Questionnaire. Pearson's correlation coefficient of difference in CRQ and team continuity: -0.041. Coefficient of conti- nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.		l trial	n=180	administration in	of Life measured with	was seen for different UPC scores.		exposure and
years which one was Chronic Respiratory regular monitor- Questionnaire. ing as adjunct to Pearson's correlation usual care coefficient of conti- nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.	vas Chronic Respiratory itor- Questionnaire. Auestionnaire. tict to Pearson's correlation coefficient of conti- nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.	vas Chronic Respiratory nitor- Questionnaire. Questionnaire. Pearson's correlation coefficient of conti- nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.	The Net	herlands	Mean age 64.5	primary care, of	self-administered	Pearson's correlation coefficient of difference in CRQ		outcome.
regular monitor- Questionnaire. ing as adjunct to Pearson's correlation usual care coefficient of conti- nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.	ittor- Questionnaire. A confision s correlation coefficient of conti- nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.	ittor- Questionnaire. Act to Pearson's correlation coefficient of conti- nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.	Data per	riod	years	which one was	Chronic Respiratory	and personal continuity: 0.117.		
Pearson's correlation coefficient of conti- nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.	uct to Pearson's correlation coefficient of conti- nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.	uct to Pearson's correlation coefficient of conti- nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.	20042	2006		regular monitor-	Questionnaire.	Pearson's correlation coefficient of difference in CRQ		
						ing as adjunct to	Pearson's correlation	and team continuity: -0.041.		
nuity of care and change in CRQ between baseline and mean of 18- and 24-month measurements.						usual care	coefficient of conti-			
change in CRQ between baseline and mean of 18- and 24-month measurements.							nuity of care and			
between baseline and mean of 18- and 24-month measurements.							change in CRQ			
and mean of 18- and 24-month measurements.							between baseline			
24-month measurements.							and mean of 18- and			
measurements.							24-month			
	<i>Table 1</i> : Summary of study characteristics and results of included studies.	<i>Table 1</i> : Summary of study characteristics and results of included studies. Notes:					measurements.			

in the finding that higher continuity of care was associated with lower health care costs. The overall result<sup>24</sup> was formulated as: "*Higher relational continuity of care for persons with asthma or COPD lowers health care costs*". The certainty of the evidence was considered to be low for the population asthma/COPD, as well as for asthma and COPD separately.

## Experience of participation in care and selfmanagement of disease

Three studies investigated various patient assessments of experience of received care, self-management of disease and quality of life.<sup>20,23,24</sup> The assessment of continuity of care was only partially relevant and the results were presented in various ways. All results were, however, consistent in their findings that higher relational continuity of care showed a positive association with experience, communication and participation<sup>20</sup>, selfmanagement of the disease<sup>23</sup> and health-related quality of life.<sup>24</sup>

The overall result was formulated as: "Higher relational continuity of care for persons with asthma or COPD may improve patients' experience of participation and knowledge about self-management of the disease." The certainty of the evidence was considered to be very low for the population asthma/COPD, and the COPD and asthma populations separately.

## Adherence to pharmacotherapy

One study with 971 participants investigated the effect of relational continuity of care on pharmacological treatment adherence.<sup>11</sup> The study was considered to have a high risk of bias, the overall certainty of the evidence was assessed as very low and, consequently, no result statement was formulated.

## Discussion

The results in this systematic review suggest that higher relational continuity of care for persons with asthma and/or COPD prevents premature deaths, lowers the risks of ED-visits and hospitalizations and lowers health care costs compared to those receiving lower levels of relational continuity of care. The certainty of the evidence was moderate for the effect on hospitalization and low for the effects on mortality, ED-visits and health care costs. The certainty of the results about adherence and experience of participation in care and self-management of the disease were very low.

To the authors' best knowledge this is the first systematic review addressing the effects of relational continuity of care in persons with asthma and/or COPD. Previously, Yang et al. performed a systematic review of the effect of different continuity of care interventions on readmission and mortality.<sup>26</sup> The included studies

Outcome	Number of studies/ participants (N)	Summarized result	Certainty of evidence according to GRADE	Reasons for reduced certainty of the evidence
Mortality	2 N=111 545	Higher relational continuity of care for persons with asthma or COPD prevents premature mortality.	Low	Risk of bias – 1 Indirectness – 0.5
Hospitalization	9 N=525 716	Higher relational continuity of care for persons with asthma or COPD lowers risk of hospitaliza- tion by a moderate to high decree	Moderate	lmprecision – 0.5 Risk of bias – 1
Emergency department visits	5 N=362 305	Higher regional contractions of the persons with asthma or COPD lowers risk of hospitaliza- tion by a modelate to high degree	Low	Risk of bias – 1 Indirectness – 1
Costs	4 N=390 685	Higher relational continuity of care for persons with asthma or COPD lowers health care costs.	Low	Risk of bias – 1 Imprecision – 1
Experience of participation in care and self-management of disease	3 N=2026	Higher relational continuity of care for persons with asthma or COPD may improve patients' experience of participation and knowledge about self-management of the disease.	Very low	Risk of bias – 1 Indirectness – 2 Immarision – 0 5
Treatment adherence	1 N=971	It is not possible to assess the effects of relational continuity of care for persons with asthma or COPD on adherence to pharmacotherapy due to the very low certainty of the evidence	Very low	Risk of bias – 2 Indirectness – 1 Imprecision – 0.5
Table 2: Summarized results and evidence ratings for the	id evidence ratings for t	the combined populations asthma or COPD.		

investigated various types of interventions, such as comprehensive care, health education and telemonitoring. Thus, they addressed management continuity rather than relational continuity. Their results implied that there was some evidence of reduced readmissions over different time frames, but there were no statistically significant findings on mortality.

The present study has some important limitations. The literature search was restricted to studies published in English from the year 2000 and onward in peer review journals. This means that relevant studies published before this, in other languages or as grey literature, might have been overlooked. All included studies, except one, were of non-randomized design, which implies an increased risk of bias due to confounding. Confounders of special concern are severity of the condition and co-morbidity, which both may affect the need for continuity of care as well as many of the outcomes studied. Most studies adjusted for one or more factors related to these issues, but residual confounding cannot be ruled out. However, if such residual confounding exists, its force would be to lower the effect results, i.e., weaken the associations. When it comes to the outcome of health care costs, a methodological challenge lies in the inclusion of outpatient visits both as part of the exposure measurement (in the form of a continuity index) and as part of the outcome. This leads to increased uncertainty around the resulting association for this particular outcome.

Publication bias was not considered to be a major problem in this research field. Most studies did not provide a study protocol or analysis plan, making the data selection time frame and the analytic approach susceptible to selection bias. There was much heterogeneity in the analytic approaches used, e.g., how measures of continuity were operationalized, analyzed and presented, making it difficult to compare results and impossible to summarize them in meta-analyses. However, the overall results were consistent in their direction, in that higher compared to lower continuity of care seems to be favorable across the range of different outcomes. This strengthens our belief in the results.

Given the heterogeneity in methods, suggestions for future research include the development and establishment of precise terms and measures for how to conduct research around continuity of care. Specific areas of interest relate to appropriate study designs, analytical methods and strategies for addressing confounding. As most published research is based on observational studies, future studies using an experimental design could provide an important complement to the existing evidence base. This kind of experimental research could aid in confirming observed effects and in studying the mechanisms underlying relational continuity of care.

In summary, this systematic review provides low to moderate certainty evidence that higher relational continuity of care for persons with asthma or COPD prevents premature mortality, lowers risks of unplanned health care utilization and lowers health care costs. These results may be of value for health professionals planning treatment and care for patients with asthma or COPD. The results can be used by policymakers for estimating possible reductions in hospitalizations and emergency department costs with increased relational continuity, for assessing different ways of organizing health care, and for developing guidelines of treatment and follow-up routines.

#### Contributors

PL JB JL MKE SE ME IE LH LA planned the study. MKE performed literature searches. PL and JB screened abstracts, PL JB SE ME IE LH and LA performed assessments of relevance and risk of bias in pairs, independently. PL JB extracted data, which was verified by SE and ME. PL JB MKE SE ME IE LH LA performed synthesis and evidence GRADINGs of results. PL wrote the first draft of the report with initial support from JB. All authors read and contributed to the final draft manuscript. All authors had access to all data/ assessed studies, and all agreed to the decision to submit.

#### **Declaration of interests**

All authors declare no competing interests.

#### Data sharing statement

All available data is provided in the manuscript.

#### Funding

None.

## Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j. eclinm.2022.101492.

#### References

- I GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8:585–596.
- 2 European Respiratory Society. The economic burden of lung disease, chapter in European White Lung book. Available at https://www.erswhitebook.org/files/public/Chapters/02\_economics.pdf. Accessed 4 May 2022.
- Haggerty J, Reid R, Freeman G, et al. Continuity of Care: A Multidisciplinary Review. *BMJ*. 2003;327:1219–1221.
  Saultz JW. Defining and measuring interpersonal continuity of
- Saultz JW. Defining and measuring interpersonal continuity of care. *Annals of family medicine*. 2004;1:134–143.
   Jee SH, Cabana MD, University of Rochester USA. Indices for con-
- 5 Jee SH, Cabana MD, University of Rochester USA. Indices for continuity of care: a systematic review of the literature. *Med Care Res Rev.* 2006;63:158–188.

- 6 Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401-406. 2011/01/07.
- 7 Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
- 8 Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *Bmj.* 2008;336:924–926. 2008/04/26.
- 9 Schünemann HJ, Cuello C, Akl EA, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105–114. 20180209.
- 10 Cho KH, Kim YS, Nam CM, et al. The Association between Continuity of Care and All-Cause Mortality in Patients with Newly Diagnosed Obstructive Pulmonary Disease: A Population-Based Retrospective Cohort Study, 2005-2012. PLoS ONE.
- II Corsico AG, Cazzoletti L, de Marco R, et al. Factors affecting adherence to asthma treatment in an international cohort of young and middle-aged adults. *Respiratory Medicine*. 2007;101:1363–1367.
- 12 Einarsdottir K, Preen DB, Emery JD, et al. Regular primary care lowers hospitalisation risk and mortality in seniors with chronic respiratory diseases. *Journal of General Internal Medicine*. 2010;25:766–773.
- 13 Frandsen BR, Joynt KE, Rebitzer JB, et al. Care fragmentation, quality, and costs among chronically ill patients. American Journal of Managed Care. 2015;21:355–362.
- 14 Hong JS, Kang HC, Kim J. Continuity of care for elderly patients with diabetes mellitus, hypertension, asthma, and chronic obstructive pulmonary disease in Korea. *Journal of Korean Medical Science*. 2010;25:1259–1271.
- Hussey PS, Schneider EC, Rudin RS, et al. Continuity and the costs of care for chronic disease. *JAMA Internal Medicine*. 2014;174:742–748.
   Kao YH, Tseng TS, Ng YY, et al. Association between continuity of
- 16 Kao YH, Tseng TS, Ng YY, et al. Association between continuity of care and emergency department visits and hospitalization in senior adults with asthma-COPD overlap. *Health Policy*. 2019;123:222–228.
- 17 Kao YH, Wu SC. Effect of Continuity of Care on Emergency Department Visits in Elderly Patients with Asthma in Taiwan. Journal of the American Board of Family Medicine: JABFM. 2017;30:384– 305.
- 18 Kao YH, Wu SC. STROBE-compliant article: Is continuity of care associated with avoidable hospitalization among older asthmatic patients? *Medicine*. 2016;95:e4948.
- 19 Lin IP, Wu SC, Huang ST. Continuity of care and avoidable hospitalizations for chronic obstructive pulmonary disease (COPD). Journal of the American Board of Family Medicine: JABFM. 2015;28:222–230.
- 20 Love MM, Mainous IAG, Talbert JC, et al. Continuity of care and the physician-patient relationship: The importance of continuity for adult patients with asthma. *Journal of Family Practice*. 2000;49:998–1004.
- 21 Svereus S, Larsson K, Rehnberg C. Clinic continuity of care, clinical outcomes and direct costs for COPD in Sweden: a population based cohort study. *European Clinical Respiratory Journal*. 2017;4: 1290193.
- 22 Swanson JO, Vogt V, Sundmacher L, et al. Continuity of care and its effect on readmissions for COPD patients: A comparative study of Norway and Germany. *Health Policy*. 2018;122:737-745.
- or Norway and Germany. Health Policy. 2018;122:737-745.
  23 Wireklint P, Hasselgren M, Montgomery S, et al. Factors associated with knowledge of self-management of worsening asthma in primary care patients a cross-sectional study. The Journal of asthma: official journal of the Association for the Care of Asthma. 2020:1-11.
- 24 Uijen AA, Bischoff EWMA, Schellevis FG, et al. Continuity in different care modes and its relationship to quality of life: A randomised controlled trial in patients with COPD. British Journal of General Practice. 2012;62:e422-e428. Article.
- 25 Levene LS, Bankart J, Khunti K, et al. Association of primary care characteristics with variations in mortality rates in England: an observational study. *PLoS ONE [Electronic Resource]*. 2012;7: e47800.
- 26 Yang F, Xiong ZF, Yang C, et al. Continuity of Care to Prevent Readmissions for Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Copd: Journal of Chronic Obstructive Pulmonary Disease. 2017;14:251–261.